264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

264.7

+1.89%↑

SAN

80.13

-0.73%↓

MRK1

108.6

-1.18%↓

SHL.DE

48.31

+2.14%↑

ARGX

657.4

+0.86%↑

Home・Aandelen Lijst・Pharming Group NV

P
Pharming Group NV

Gesloten

1.27 4.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.212

Max

1.293

Belangrijke statistieken
By Trading Economics
Inkomsten	19M 4.7M
Verkoop	14M 93M
EPS	0.006
Winstmarge	5.035
Werknemers	404

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+97.24% upside

Dividenden
By Dow Jones
Volgende Winsten	6 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	233M 850M
Vorige openingsprijs	-3.52
Vorige sluitingsprijs	1.27

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 sep 2025, 23:37 UTC

Populaire aandelen

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sep 2025, 20:41 UTC

Winsten

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sep 2025, 20:30 UTC

Winsten

GameStop 2Q Sales, Profit Rise

9 sep 2025, 23:19 UTC

Marktinformatie

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sep 2025, 21:35 UTC

Winsten

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sep 2025, 21:32 UTC

Winsten

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sep 2025, 21:02 UTC

Acquisities, Fusies, Overnames

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 sep 2025, 20:33 UTC

Winsten

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sep 2025, 20:26 UTC

Winsten

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sep 2025, 20:23 UTC

Winsten

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sep 2025, 20:12 UTC

Winsten

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sep 2025, 20:10 UTC

Winsten

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sep 2025, 20:10 UTC

Winsten

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sep 2025, 20:09 UTC

Winsten

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sep 2025, 20:09 UTC

Winsten

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sep 2025, 20:08 UTC

Winsten

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sep 2025, 20:08 UTC

Winsten

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sep 2025, 20:08 UTC

Winsten

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sep 2025, 20:08 UTC

Winsten

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sep 2025, 20:07 UTC

Winsten

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sep 2025, 20:06 UTC

Winsten

Oracle 1Q Software Revenue $5.72B >ORCL

9 sep 2025, 20:06 UTC

Winsten

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sep 2025, 20:06 UTC

Winsten

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Rev $14.93B >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q EPS $1.01 >ORCL

9 sep 2025, 20:05 UTC

Winsten

Synopsys 3Q EPS $1.50 >SNPS

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Services Revenue $1.35B >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Adj EPS $1.47 >ORCL

9 sep 2025, 20:05 UTC

Winsten

Oracle 1Q Hardware Revenue $670M >ORCL

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Koersdoel

By TipRanks

97.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.446 EUR 97.24%

Hoogste 2.45 EUR

Laagste 2.45 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pharming Group NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Pharming Group NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.